# Phio Pharmaceuticals Corp. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Phio Pharmaceuticals Corp.). ## Overview Phio Pharmaceuticals Corp. is a U.S.-based clinical-stage biotechnology company focused on developing RNAi-based immuno-oncology therapies. Through its subsidiary MirImmune, LLC, the company advances INTASYL drug candidates such as PH-762 and PH-894 for potential use in cancer treatment. ## Products & services • INTASYL RNAi therapeutic platform • PH-762 immuno-oncology candidate • PH-894 preclinical oncology candidate • Preclinical and IND-enabling development • Patent prosecution for therapeutic compounds - **RNAi therapeutic platform** (40%) — INTASYL-based RNA interference technology used to silence target genes in immune and cancer cells. - **Clinical-stage oncology candidates** (35%) — Lead and pipeline drug candidates being developed for immuno-oncology applications. - **Preclinical development services** (15%) — IND-enabling studies, translational research, and early-stage development work. - **Intellectual property portfolio** (10%) — Patents and pending applications covering compounds, technologies, and geographic protection. - INTASYL RNAi therapeutic platform - PH-762 immuno-oncology candidate - PH-894 preclinical oncology candidate - Preclinical and IND-enabling development - Patent prosecution for therapeutic compounds ## Customers Phio does not sell commercial products today; its primary counterparties are clinical collaborators, research vendors, regulators, and capital providers that support drug development. If its candidates advance, the eventual customers would be oncology patients through physicians and healthcare systems, with adoption depending on clinical efficacy, safety, and regulatory approval. - **Clinical development partners** (primary) — Research organizations and collaborators that support preclinical studies, assay work, and trial execution. - **Regulatory agencies** (primary) — U.S. and other regulators that review IND submissions and clinical packages for PH-762 and PH-894. - **Future oncology prescribers** (emerging) — Oncologists and cancer centers that would use approved therapies if the pipeline reaches commercialization. - **Capital providers** (primary) — Equity and debt investors that fund ongoing R&D and public-company operations. - Clinical collaborators supporting preclinical and translational work - CROs and research vendors conducting studies and trials - Regulators reviewing IND and clinical development packages - Future oncologists and hospitals if a therapy is approved - Investors and financing partners funding development ## Geography Phio is headquartered in the United States and concentrates its development and patent activity there, while also maintaining patent coverage in Canada, Europe, Japan, and other markets. Its operational footprint is primarily U.S.-based, but its intellectual property strategy reflects a broader international protection approach for future partnering and commercialization. - Headquartered and primarily operated in the United States - U.S. is the main focus for clinical development and IND activity - Patent coverage extends to Canada, Europe, Japan, and other markets - International IP matters for partnering and future commercialization - No revenue geography disclosed because the company is pre-commercial ## Strategy Phio’s strategy centers on advancing its lead immuno-oncology candidate PH-762 while continuing preclinical work on PH-894 and protecting the INTASYL platform through patents. The company also prioritizes capital preservation and financing access so it can fund development through regulatory milestones and potential partnering opportunities. - **Advance PH-762 clinical development** (short-term) — The lead candidate is the main path to value creation and potential partnering. - **Prepare PH-894 for IND submission** (medium-term) — Broadens the pipeline and creates a second development asset. - **Protect and rationalize IP portfolio** (medium-term) — Patent coverage supports exclusivity and future licensing leverage. - **Secure development funding** (short-term) — Clinical biotechnology requires ongoing external capital before product revenue exists. - Advance PH-762 through clinical development - Complete IND-enabling work for PH-894 - Protect INTASYL intellectual property in key markets - Preserve cash to fund development milestones - Maintain access to public-market financing ## Risks Phio faces the typical risks of a pre-commercial biotech company: clinical and regulatory uncertainty, dependence on external financing, and the possibility that candidates do not demonstrate sufficient safety or efficacy. The company also has specific listing and liquidity risks tied to Nasdaq compliance, which can affect market access and financing flexibility. - **Nasdaq continued listing compliance** [high] — The company must maintain minimum bid price and equity requirements to remain listed. - **Clinical development failure** [critical] — Drug candidates may not show sufficient efficacy or safety in preclinical or clinical testing. - **Financing dependence** [high] — Operations are funded primarily through external capital until any product revenue exists. - **Supply and trade policy disruption** [medium] — Research and development inputs may be delayed or become more expensive. - Clinical trials may fail or produce inconclusive results - Regulatory approval is uncertain and time-consuming - External financing is needed before product revenue - Nasdaq listing compliance affects liquidity and capital access - Trade policy and supply disruptions can affect research operations ## Accounting As a pre-revenue biotech, Phio’s reported results are driven mainly by R&D expense timing, stock compensation, and other operating costs rather than product sales. Investors should watch estimates around clinical and preclinical accruals, equity financing effects, and going-concern disclosures, since these can materially affect comparability and balance-sheet presentation. - **Research and development accruals** — Affects operating expense timing and liabilities - **Stock-based compensation** — Affects operating expenses and equity - **Going-concern assessment** — Affects disclosure and investor perception - **Equity financing and reverse stock splits** — Affects dilution and comparability - R&D expense timing depends on study and trial activity - Stock-based compensation can materially affect operating costs - Clinical accruals and vendor estimates affect liabilities - Going-concern disclosure reflects funding uncertainty - Equity financing and reverse splits affect share counts --- *Last updated: 2026-04-29T04:48:40.493382+00:00*